Literature DB >> 2543075

Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

J E Hildreth1, R J Orentas.   

Abstract

Cell fusion (syncytium formation) is a major cytopathic effect of infection by human immunodeficiency virus (HIV) and may also represent an important mechanism of CD4+ T-cell depletion in individuals infected with HIV. Syncytium formation requires the interaction of CD4 on the surface of uninfected cells with HIV envelope glycoprotein gp120 expressed on HIV-infected cells. However, several observations suggest that molecules other than CD4 play a role in HIV-induced cell fusion. The leukocyte adhesion receptor LFA-1 is involved in a broad range of leukocyte interactions mediated by diverse receptor-ligand systems including CD4-class II major histocompatibility complex (MHC) molecules. Possible mimicry of class II MHC molecules by gp120 in its interaction with CD4 prompted an examination of the role of LFA-1 in HIV-induced cell fusion. A monoclonal antibody against LFA-1 completely inhibited HIV-induced syncytium formation. The antibody did not block binding of gp120 to CD4. This demonstrates that a molecule other than CD4 is also involved in cell fusion mediated by HIV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543075     DOI: 10.1126/science.2543075

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  87 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.

Authors:  D H Nguyen; J E Hildreth
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

6.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Glycosylphosphatidylinositol-anchored CD4 supports human immunodeficiency virus type 1 replication, but not cytopathic effect, in T-cell transfectants.

Authors:  W L Marshall; E S Mittler; P Avery; J P Lawrence; R W Finberg
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Increased CD11/CD18 expression on the peripheral blood leucocytes of patients with HIV disease: relationship to disease severity.

Authors:  S Palmer; A S Hamblin
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

Authors:  Y Tani; E Donoghue; S Sharpe; E Boone; H C Lane; S Zolla-Pazner; D I Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type I- and type II-infected T cells by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  M Wolfson; M Lev; I Avinoah; Z Malik; M Löchelt; R M Flügel; A Dombrovski; M Aboud
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.